Soleus Capital Management, L.P. Krystal Biotech, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 216,979 shares of KRYS stock, worth $33.2 Million. This represents 3.35% of its overall portfolio holdings.
Number of Shares
216,979
Previous 126,000
72.21%
Holding current value
$33.2 Million
Previous $23.1 Million
70.53%
% of portfolio
3.35%
Previous 2.34%
Shares
16 transactions
Others Institutions Holding KRYS
# of Institutions
309Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$604 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$436 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$401 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$222 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$151 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.92B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...